9th IAS Conference "HIV Science", 23-26 July 2017, Paris: Approximately 3000 people treated with Truvada PrEP (pre-exposure prophylaxis) for HIV-1 before the marketing authorization.

National Agency for the Safety of Medicines and Health Products (ANSM) emphasized the eradication of HIV. France is a main actor of public health in Europe and around the world . Therefore,  an investigation of TRUVADA PrEP will be discussed for the treatment of HIV prevention. Hence, ongoing clinical trial result will be collected when effectiveness and safety approved the product will be launched to the European market.

Truvada PrEP HIV, early access protocolized in France via a Temporary Use Recommendation: approximately 3000 people treated before the marketing authorization.

http://ansm.fr